Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,279 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection
Interventions: Posoleucel (ALVR105); Biological
Lead sponsor: AlloVir; Industry
Eligibility: 1 Year and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 16
States / cities: Birmingham, Alabama • Duarte, California • San Francisco, California + 12 more

Conditions: Wound Infection
Interventions: Prevena Incision Management System, Dermabond; Device
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Buffalo, New York

Conditions: COVID-19 Prevention
Interventions: Q-Griffithsin, Placebo; Drug · Other
Lead sponsor: Kenneth Palmer; Other
Eligibility: 18 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Recurrence of Clostridium Difficile Infection
Interventions: REBYOTA™; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 42
States / cities: Chandler, Arizona • Chula Vista, California • Murrieta, California + 36 more

Conditions: Hospital Acquired Infection
Interventions: Copper impregnated linen; Other
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Sex Work
Interventions: Community based combination HIV prevention package; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV, Hematologic Malignancies
Interventions: RIC, GVHD prophylaxis, allo HCT, Plerixafor, Maraviroc; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 120 Years
Enrollment: 265 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: MVA-CMDR, Placebo; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Sexually Transmitted Diseases
Interventions: Horizons+General Health Promotion (GHP), Horizons+Motivational Enhancement Therapy (GMET); Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 24 Years · Female only
Enrollment: 560 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Respiratory Syncytial Virus Infections
Interventions: MEDI8897, Placebo; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: Up to 365 Days
Enrollment: 1,453 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 60
States / cities: Birmingham, Alabama • Anaheim, California • Downey, California + 53 more

Conditions: HIV Infections
Interventions: HIV-related text messaging, Nutrition-related text messaging; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 16 Years to 20 Years · Male only
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: MRSA Infections
Interventions: Not listed
Lead sponsor: CAMC Health System; Other
Eligibility: 18 Years to 90 Years
Enrollment: 169 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Bacteremia
Interventions: Heparin 1000U/mL, 4% Sodium Citrate with Gentamicin 320 mcg/mL; Drug
Lead sponsor: Satellite Healthcare; Other
Eligibility: Not listed
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Mountain View, California

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: moxifloxacin hydrochloride, Placebo; Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Covid19
Interventions: RTB101, Placebo; Drug
Lead sponsor: Restorbio Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Farmington, Connecticut • Roslindale, Massachusetts

Conditions: HIV Infections
Interventions: PrEP; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Self Efficacy, HIV Prevention, STI Prevention
Interventions: Treat Act Know Engage (T.A.K.E.) Steps, Standard or Care; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 13 Years to 19 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Philadelphia, Pennsylvania

Conditions: Sexually Transmitted Diseases, HIV Infections
Interventions: Healthy Relationships; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 24 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Urinary Tract Infection
Interventions: E. coli 83972 coated urinary catheter; Device
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Truvada, Genvoya; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Marburg Hemorrhagic Fever
Interventions: AVI-6003, Placebo; Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Cypress, California

Conditions: Malaria
Interventions: Mefloquine, Control; Drug · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Dengue Fever
Interventions: rDEN1delta30, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Complicated Appendicitis, Acute Appendicitis
Interventions: Ceftriaxone, Intra-peritoneal Fluid Aspiration; Drug · Procedure
Lead sponsor: Johns Hopkins All Children's Hospital; Other
Eligibility: 3 Years to 18 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: St. Petersburg, Florida

Search by objective public record fields.

Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

Prevena™ vs Dermabond in Groin Wound Infections in Vascular Surgery

PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray

REBYOTA™ Prospective Registry

Effect of Copper Impregnated Textiles on Healthcare Associated Infections and Antibiotic Use

A Structural HIV Prevention Intervention Targeting High-risk Women

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

Project N-Liten- HIV Prevention for African American Women

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.

Effectiveness of a Cell Phone-Based Program for Abstinence and HIV Risk Prevention

Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis

Prophylactic Antimicrobial Catheter Lock

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults

Project EMPOWERING: Evidence-based PrEP for Justice-Involved Women and Their Risk Networks

TAKE Steps: Motivational Interviewing to Prevent STIs

Adopting and Demonstrating the Adaptation of Prevention Techniques (ADAPT), Harlem United Community AIDS Center

Bacterial Interference for Prevention of Catheter-Associated UTI: Geriatric Pilot Study

Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus

Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults

Antibiotic Instillation in Appendicitis